2020-07-09 16:53:13 - WHO

Addressing the crisis in antibiotic development


Today, more than 20 leading biopharmaceutical companies are announcing the launch of the AMR Action Fund that will invest in developing innovative antibacterial treatments. The Fund aims to bring 2-4 new treatments to patients by 2030. This initiative is a significant step towards addressing the current crisis in antibacterial treatment development. AMR is a slow tsunami that threatens to undo a century of medical progress highlighted Dr Tedros, Director General of the WHO at the launch event in Berlin. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis. The AMR Action Fund is the result of collaboration among major pharmaceutical companies, the European Investment Bank (EIB), Wellcome Trust and WHO. Since 2018, WHO and the EIB have been advancing an overall concept for an impact investment fund to support the development of antibacterial treatment for public health priorities. This concept was presented and discussed in several international fora including at the Biocom AMR Conference, the World Health Summit in Berlin, and the World AMR Congress in Washington. In 2019, a financial model was developed to assess the risks, success rates and the potential financial return of investment in new antibacterial treatments. WHO then played a catalytic role in bringing together the International Federation of Pharmaceutical Manufacturers Associations, the EIB and Wellcome Trust, providing critical input on the public health priorities and the investment strategy of the AMR Action Fund.Recent bankruptcies have shown how small antibiotics companies struggle to survive in the current market environment. The process of getting new drugs to market is cost intensive as new antibacterial treatments have to be underpinned with rigorous data that are derived from a series of complex and costly clinical trials to demonstrate their advantages over existing treatment regimens.The AMR Action Fund will invest, through equity or debt, in small companies developing innovative antibacterial treatments that target existing AMR Action Fund through equity or debt, in small companies developing innovative antibacterial treatments that target existing public health priorities. The annual reviews conducted by WHO of both the preclinical and clinical antibiotic pipeline, together with the recently published target product profiles for missing treatments, will provide detailed guidance in this regard. The WHO review of the clinical antibiotic pipeline identifies a number of potential investment candidates. Currently, there are only 32 antibacterial treatments, in clinical development, targeting the WHO s list of priority pathogens and of these, only 6 fulfil at least one of the innovation criteria as defined by WHO. The latest WHO review of the preclinical pipeline revealed that new and innovative approaches are emerging in the development of antibacterial of the 252 antibacterial agents that were in preclinical development, over one-third were non-traditional products. The next WHO clinical pipeline review will expand to include non-traditional products such as phages and other new innovative approaches to overcome antibacterial resistance. Investment to ensure promising antibacterial treatments successfully move through to market is a critical step in tackling AMR, said Dr Haileyesus Getahun, Director of the Department of Global Coordination and Partnership (GCP) on AMR at WHO. WHO stands ready to support the AMR Action Fund in its focus on public health priorities and innovative new antibacterial treatments. While the AMR Action Fund is an important step in addressing the challenge of AMR, it will only partly compensate for the rapidly diminishing flow of investment from the private sector and from public funding. Partnerships like the AMR Action Fund, including CARB-X and the Global Antibiotic Research and Development Partnership (GARDP), bring together relevant stakeholders and play a crucial synergistic role in improving the current pipeline of antibacterial treatments. GARDP, a foundation that was set up by WHO and the Drugs for Neglected Diseases initiative (DNDi) to develop new treatments for drug-resistant infections posing the greatest threat to public health, is playing an important role in mobilizing more funding from both public and private sectors for public health priorities. GARDP recently partnered with a small company on an innovative beta-lactamase inhibitor that works against serious multidrug resistant bacterial infections. The launch of the AMR Action Fund represents an important step towards revitalizing antibacterial drug development and also creates the opportunity to address the much needed reforms of the current procurement and reimbursement systems for new treatments.

Read on the original site






WHO
Study provides comprehensive view of terrestrial venomous snakes and snakebite in the Middle East
World Hepatitis Day: fast-tracking the elimination of hepatitis B among mothers and children
Cervical Cancer Elimination Initiative Updates
Addressing the crisis in antibiotic development
The World Health Organization reminds public to remain vigilant through Mr Bean’s Essential COVID-19 Checklist
Countries failing to prevent violence against children, agencies warn
First rituximab similar biotherapeutic products prequalified
The value of integrating HIV prevention and contraceptive services
Statement from Dr Mike Ryan, Executive Director, WHO Health Emergencies Programme at the Yemen High-level Pledging Conference
Maintaining essential health services: new operational guidance for the COVID-19 context
Basic Psychosocial Skills: A Guide for COVID-19 Responders
FIFA, European Commission and World Health Organization launch #SafeHome campaign to support those at risk from domestic violence
Historic health assembly ends with global commitment to COVID-19 response
Meeting of the Global Network of WHO Collaborating Centres for Bioethics
WHO and International Olympic Committee team up to improve health through sport
WHO and Costa Rica preview technology pooling initiative to ensure access to COVID-19 health products for all
Online Survey for Health Professionals on a Healthy Recovery from COVID-19
Research leads to actions improving childbirth in Guinea
Launch of the online courses on tobacco product regulation
Substantial investment needed to avert mental health crisis
WHO News
Member States adopt the Global Strategy for TB Research and Innovation at 73rd World Health Assembly
WHO at the virtual High-level Political Forum (HLPF) 2020
Plane carrying WHO trauma and surgical supplies arrives in Beirut, Lebanon
Mexico’s feat against rabies through cross-sectoral collaboration is possible in other countries
73rd World Health Assembly Decisions
WHO Information Notice for Users of Medical Devices 2020/3
New Science Council to be established
Statement on the fourth meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of coronavirus disease (COVID-19)
COVID-19 Emergency Committee highlights need for response efforts over long term
World Breastfeeding Week 2020 Message
WHO, WIPO, WTO launch updated study on access to medical technologies and innovation
INFOSAN Quarterly Summary, 2020 #2
Framework for the evaluation of new tests for tuberculosis infection
Children are the key to behaviour change to reduce infection
WHO statement on heated tobacco products and the US FDA decision regarding IQOS
European Medicines Agency (EMA) approval of the dapivirine ring for HIV prevention for women in high HIV burden settings
Amid continued progress, trachoma elimination programmes set their sights on 2030
New estimates show worldwide fall in unintended pregnancies since 1990-1994
Call for expressions of interest: Systematic reviews on dose optimization of the first-line TB medicines
New COVID-19 Law Lab to provide vital legal information and support for the global COVID-19 response
RT
Americans give up citizenship in record-smashing numbers as expats find ‘pandemic political climate too much to bear’ – report
Most US voters don t think Biden will be able to finish his full four-year term if elected president - poll
Rules for thee but not for me: Pompeo denounces proposed Russian law as ‘burdensome’ limitation on US propaganda outlets
‘Give them soy lattes and foot massages’ – Ted Cruz roasted for mocking pandemic payments
Massive dragon-shaped windstorm headed for Chicago
White House on lockdown, Trump press conference interrupted after reports of shots fired
One KILLED in massive protests in Minsk as demonstrators clash with Belarus police
Explosions reported as Iraqi Shiite militia targets US military convoy near Kuwait border - security forces
Ooops: Belarus police almost load arrested protester into CITY BUS by mistake
Belarus: Images of troops in camouflage uniform confronting protesters emerge amid brutal arrests
Nikki Haley hit with avalanche of Twitter mockery and vitriol for daring to complain about tardy popcorn deliveries
Russian watchdog says Apple abused dominance of mobile app market, orders US tech giant to stop restricting competition
Belarus on the brink? Unloved in Moscow, a pariah again in the West facing protests at home, Lukashenko is running out of road
Beirut protesters tell RT they won t leave streets until ENTIRE PARLIAMENT steps down after PM’s resignation
McDonald’s sues ex-CEO over CONSENSUAL flings: A virtue-signalling distraction for firm plagued with sex harassment probes?
KGB of Belarus says it stopped ‘assassination’ plot against opposition candidate Tikhanovskaya
‘We are coming for you’: Chicago mayor promises CRACKDOWN after night of ‘straight-up felony’
German basketball player urged to take legal action after being fired over coronavirus protest with athlete girlfriend
What could it mean? Twitter erupts with sarcastic suggestions after Trump refers to himself as ‘President T’
Slovakia expels 3 staff at Russian embassy, Moscow ‘will retaliate’